Hetero, one of India’s leading generic pharmaceutical companies, announced the launch of biosimilar ‘Bevacizumab’ in India for the treatment of metastatic colorectal cancer (mCRC) under the brand name ‘Cizumab’.
The product has been approved by Drug Controller General of India (DCGI) and has been recommended as a first-line treatment for mCRC. The product will be made available to patients in a single dose vial with two strengths, 100 mg and 400 mg. It will be marketed and distributed by Hetero Healthcare Limited, a group company of Hetero.
Commenting on the launch of the product, Dr BPS Reddy, CMD, Hetero Group of Companies said, “It has been an exciting journey for us in biologics. Hetero’s Bevacizumab is the third product in our biologics portfolio, after Darbepoetin alfa and Rituximab. We believe Cizumab will be a cost-effective treatment option to patients in India.”
The product will be manufactured in our dedicated state-of-the-art biologics facility based in Hyderabad, India.